Prediction markets are putting a price on pharma's secrets. Here's what companies need to know.

Prediction markets expanding into clinical trial outcomes pose new risks for pharma companies, signalling the need to monitor not just employees but also external partners who access sensitive data.

This Wire brief sits within Fusion42's coverage of Biotech.